1- Dental Research Center, Golestan University of Medical Sciences, Gorgan, Iran
2- Dental Research Center, Golestan University of Medical Sciences, Gorgan, Iran. Department of Oral and Maxillofacial Medicine, School of Dentistry, Golestan University of Medical Sciences, Gorgan, Iran ,mortazavi_nazanin@yahoo.com
3- Health Management and Social Development Research Center, Golestan University of Medical Sciences, Gorgan, Iran
4- Medical Librarianship and Information Sciences, Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
5- Stem Cell Research Center, Golestan University of Medical Sciences, Gorgan, Iran
2- Dental Research Center, Golestan University of Medical Sciences, Gorgan, Iran. Department of Oral and Maxillofacial Medicine, School of Dentistry, Golestan University of Medical Sciences, Gorgan, Iran ,
3- Health Management and Social Development Research Center, Golestan University of Medical Sciences, Gorgan, Iran
4- Medical Librarianship and Information Sciences, Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
5- Stem Cell Research Center, Golestan University of Medical Sciences, Gorgan, Iran
Abstract: (604 Views)
Background: Oral cancer is the sixth most common cancer in the world and the third most common cancer in developing countries. Early detection of oral cancer can reduce mortality in several ways. The aim of the present study was to combine the quantitative results of various studies concerning serum and salivary microRNAs for early diagnosis of head and neck squamous cell carcinoma (HNSCC).
Methods: This systematic review and meta-analysis was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guideline. We searched all the relevant English studies in international databases of PubMed/Medline, Scopus, Web of Science, Cochrane, ProQuest, Embase, and Wiley until February 2022. A random-effects model was used to estimate the pooled odds ratio (OR) and its corresponding 95% confidence interval (CI) for each study. A total of 672 articles were found. After screening, 93 articles were approved for systematic review. Finally, 5 completely relevant articles were examined in the meta-analysis.
Results: Considering all studies regarding miRNAs, the combined results indicated that AUC = 0.73, with a sensitivity of 71.68% and a specificity of 69.95%, could be used for HNSCC diagnosis. Due to the moderate sensitivity and specificity of miRNAs, they may be able to confirm or exclude suspected cases of this disease, enhancing their utility as clinical diagnostic indicators.
Conclusion: The available data provide evidence that miRNAs, especially MiR-31 expression in the saliva, serum, or plasma, can be used as a diagnostic biomarker for HNSCC patients. However, controlled clinical trials with large sample sizes are needed to validate different miRNAs.
Methods: This systematic review and meta-analysis was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guideline. We searched all the relevant English studies in international databases of PubMed/Medline, Scopus, Web of Science, Cochrane, ProQuest, Embase, and Wiley until February 2022. A random-effects model was used to estimate the pooled odds ratio (OR) and its corresponding 95% confidence interval (CI) for each study. A total of 672 articles were found. After screening, 93 articles were approved for systematic review. Finally, 5 completely relevant articles were examined in the meta-analysis.
Results: Considering all studies regarding miRNAs, the combined results indicated that AUC = 0.73, with a sensitivity of 71.68% and a specificity of 69.95%, could be used for HNSCC diagnosis. Due to the moderate sensitivity and specificity of miRNAs, they may be able to confirm or exclude suspected cases of this disease, enhancing their utility as clinical diagnostic indicators.
Conclusion: The available data provide evidence that miRNAs, especially MiR-31 expression in the saliva, serum, or plasma, can be used as a diagnostic biomarker for HNSCC patients. However, controlled clinical trials with large sample sizes are needed to validate different miRNAs.
Type of Article: Systematic Review and Meta Analysis |
Subject:
Basic Medical Sciences
Received: 2023/10/28 | Accepted: 2024/01/14 | Published: 2023/12/30
Received: 2023/10/28 | Accepted: 2024/01/14 | Published: 2023/12/30
References
1. Jiang J-S, Zhu J, Han H, Wang Q. Expression of Oct-4 in oncogenic miR-155-positive oral squamous carcinoma cells. 2016;15(9):1847-52. [View at Publisher] [DOI] [Google Scholar]
2. Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, et al. Salivary microRNA: Discovery, Characterization, and Clinical Utility for Oral Cancer Detection. Clin Cancer Res. 2009;15(17):5473-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. Tian X, Chen Z, Shi S, Wang X, Wang W, Li N, et al. Clinical diagnostic implications of body fluid miRNA in oral squamous cell carcinoma: A meta-analysis. Medicine (Baltimore). 2015;94(37):e1324. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Dumache R, Rogobete AF, Andreescu N, Puiu MJCL. Genetic and epigenetic biomarkers of molecular alterations in oral carcinogenesis. 2015;61(10):1373-81. [View at Publisher] [DOI] [Google Scholar]
5. Glick M, William MJS. CT: PMPH-USA Ltd. Burket's Oral medicine. 12th ed. New York: Buffalo; 2015. p.250 [View at Publisher] [Google Scholar]
6. Liu CJ, Lin SC, Yang CC, Cheng HW, Chang KW. neck. Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. 2012;34(2):219-24. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Karimi A, Bahrami N, Sayedyahossein A, Derakhshan SJJoOP. Medicine. Evaluation of circulating serum 3 types of microRNA as biomarkers of oral squamous cell carcinoma; A pilot study. 2020;49(1):43-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
8. Ishinaga H, He F, Hou B, Shah S, Murata M, Takeuchi K. A longitudinal study on circulating miR-21 as a therapeutic effect marker in head and neck squamous cell carcinoma. Carcinogenesis. 2019;40(9):1070-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
9. Yap T, Seers C, Koo K, Cheng L, Vella L, Hill A, et al. Non-invasive screening of a microRNA-based dysregulation signature in oral cancer and oral potentially malignant disorders. Oral Oncol. 2019;96:113-20. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Wiklund ED, Gao S, Hulf T, Sibbritt T, Nair S, Costea DE, et al. MicroRNA alterations and associated aberrant DNA methylation patterns across multiple sample types in oral squamous cell carcinoma. PLoS ONE. 2011;6(11):e27840. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. Yılmaz K, Gümüşay Ö, Nursal AF, Karakuş N, Yiğit S. Genetic Variations of miRNAs and the Risk of Oral Squamous Cell Carcinoma: A Case-control Study.Medical Bulletin of Haseki/Haseki Tip Bulteni. 2020;58(3):268-73. [View at Publisher] [DOI] [Google Scholar]
12. Hung P-S, Liu C-J, Chou C-S, Kao S-Y, Yang C-C, Chang K-W, et al. miR-146a enhances the oncogenicity of oral carcinoma by concomitant targeting of the IRAK1, TRAF6 and NUMB genes. PLoS ONE. 2013;8(11):e79926. [View at Publisher] [DOI] [PMID] [Google Scholar]
13. Lerner C, Bochen F, Kulas P, Linxweiler M, Hasenfus A, Heinzelmann J, et al. 149 Influence of miR-146a and miR-155 on cell proliferation and migration in head and neck squamous cell carcinoma. Eur J Cancer. 2015;3(51):14. [View at Publisher] [DOI] [Google Scholar]
14. Wang L-L, Li H-X, Yang Y-Y, Su Y-L, Lian J-S, Li T, et al. MiR-31 is a potential biomarker for diagnosis of head and neck squamous cell carcinoma. Int J Clin Exp Pathol. 2018;11(9):4339-45. [View at Publisher] [Google Scholar]
15. Liu CJ, Kao SY, Tu HF, Tsai MM, Chang KW, Lin SC. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis. 2010;16(4):360-4. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Scholtz B, Horváth J, Tar I, Kiss C, Márton IJJP. Salivary miR-31-5p, miR-345-3p, and miR-424-3p Are Reliable Biomarkers in Patients with. Oral Squamous Cell Carcinoma. 2022;11(2):229. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Dioguardi M, Caloro GA, Laino L, Alovisi M, Sovereto D, Crincoli V, et al. Circulating miR-21 as a potential biomarker for the diagnosis of oral cancer: A systematic review with meta-analysis. Cancers. 2020;12(4):936. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Kozaki K-i, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res. 2008;68(7):2094-105. [View at Publisher] [DOI] [PMID] [Google Scholar]
19. Lajer C, Garnaes E, Friis-Hansen L, Norrild B, Therkildsen M, Glud M, et al. The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. Br J Cancer. 2012;106(9):1526-34. [View at Publisher] [DOI] [PMID] [Google Scholar]
20. Wong TS, Liu XB, Wong BYH, Ng RWM, Yuen APW, Wei WI. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res. 2008;14(9):2588-92. [View at Publisher] [DOI] [PMID] [Google Scholar]
21. Rapado-González O, Martínez-Reglero C, Salgado-Barreira A, López-López R, Suárez-Cunqueiro M, Muinelo-Romay L. miRNAs in liquid biopsy for oral squamous cell carcinoma diagnosis: Systematic review and meta-analysis. Oral Oncol. 2019;99:104465. [view at publisher] [DOI] [PMID] [Google Scholar]
22. Lu Z, He Q, Liang J, Li W, Su Q, Chen Z, et al. miR-31-5p is a potential circulating biomarker and therapeutic target for oral cancer. Mol Therapy-Nucleic Acids. 2019;16:471-80. [view at publisher] [DOI] [PMID] [Google Scholar]
23. Mahmood N, Hanif M, Ahmed A, Jamal Q, Mushtaq S, Khan A, et al. Circulating miR-21 as a prognostic and predictive biomarker in oral squamous cell carcinoma. Pak J Med Sci. 2019;35(5):1408-12. [view at publisher] [DOI] [PMID] [Google Scholar]
24. Mehdipour M, Shahidi M, Manifar S, Jafari S, Abbas FM, Barati M, et al. Diagnostic and prognostic relevance of salivary microRNA-21,-125a,-31 and-200a levels in patients with oral lichen planus-a short report. Cell Oncol. 2018;41(3):329-34. [view at publisher] [DOI] [PMID] [Google Scholar]
25. Momen-Heravi F, Bala S. Extracellular vesicles in oral squamous carcinoma carry oncogenic miRNA profile and reprogram monocytes via NF-κB pathway. Oncotarget. 2018;9(78):34838-34854. [view at publisher] [DOI] [PMID] []
26. Singh P, Srivastava AN, Sharma R, Mateen S, Shukla B, Singh A, et al. Circulating microRNA-21 expression as a novel serum biomarker for oral sub-mucous fibrosis and oral squamous cell carcinoma. Asian Pac J Cancer Prev. 2018;19(4):1053-7. [view at publisher] [DOI] [PubMed] [Google Scholar]
27. Yap T, Koo K, Cheng L, Vella LJ, Hill AF, Reynolds E, et al. Predicting the Presence of Oral Squamous Cell Carcinoma Using Commonly Dysregulated MicroRNA in Oral SwirlsOSCC Prediction from MicroRNA in Oral Swirls. 2018;11(8):491-502. [view at publisher] [DOI] [PMID] [Google Scholar]
28. Wei L, Mao M, Liu H. Droplet digital PCR and qRT-PCR to detect circulating miR-21 in laryngeal squamous cell carcinoma and pre-malignant laryngeal lesions. Acta Otolaryngol. 2016;136(9):923-32. [view at publisher] [DOI] [PMID] [Google Scholar]
29. Yan Y, Wang X, Venø MT, Bakholdt V, Sørensen JA, Krogdahl A, et al. Circulating miRNAs as biomarkers for oral squamous cell carcinoma recurrence in operated patients. Oncotarget. 2017;8(5):8206-14. [view at publisher] [DOI] [PMID] []
30. Zahran F, Ghalwash D, Shaker O, Al-Johani K, Scully C. Salivary micro RNA s in oral cancer. Oral Dis. 2015;21(6):739-47. [view at publisher] [DOI] [PMID] [Google Scholar]
31. Ren W, Qiang C, Gao L, Li S-M, Zhang L-M, Wang X-L, et al. Circulating microRNA-21 (MIR-21) and phosphatase and tensin homolog (PTEN) are promising novel biomarkers for detection of oral squamous cell carcinoma. Biomarkers. 2014;19(7):590-6. [view at publisher] [DOI] [PMID] [Google Scholar]
32. Hsu C-M, Lin P-M, Wang Y-M, Chen Z-J, Lin S-F, Yang M-Y. Circulating miRNA is a novel marker for head and neck squamous cell carcinoma. Tumor Biology. 2012;33(6):1933-42. [view at publisher] [DOI] [PMID] [Google Scholar]
33. Jung HM, Phillips BL, Patel RS, Cohen DM, Jakymiw A, Kong WW, et al. Keratinization-associated miR-7 and miR-21 regulate tumor suppressor reversion-inducing cysteine-rich protein with kazal motifs (RECK) in oral cancer. J Biol Chem. 2012;287(35):29261-72. [view at publisher] [DOI] [PMID] []
34. Chen M, Luo R, Li S, Li H, Qin Y, Zhou D, et al. based strip for ultrasensitive detection of OSCC-associated salivary microRNA via CRISPR/Cas12a coupling with IS-primer amplification reaction. Anal Chem. 2020;92(19):13336-42. [view at publisher] [DOI] [PMID] [Google Scholar]
35. Yan Y, Yan F, Huang Q. MiR-200c inhibited the proliferation of oral squamous cell carcinoma cells by targeting Akt pathway and its downstream Glut1. Arch Oral Biol. 2018;96:52-7. [view at publisher] [DOI] [PMID] [Google Scholar]
36. Sun G, Cao Y, Wang P, Song H, Bie T, Li M, et al. miR-200b-3p in plasma is a potential diagnostic biomarker in oral squamous cell carcinoma. Biomarkers. 2018;23(2):137-41. [view at publisher] [DOI] [PMID] [Google Scholar]
37. Wang Z, Zhang J, Guo Y, Wu X, Yang W, Xu L, et al. A novel electrically magnetic-controllable electrochemical biosensor for the ultra sensitive and specific detection of attomolar level oral cancer-related microRNA. Biosens Bioelectron. 2013;45:108-13. [view at publisher] [DOI] [PMID] [Google Scholar]
38. He L, Ping F, Fan Z, Zhang C, Deng M, Cheng B, et al. Salivary exosomal miR-24-3p serves as a potential detective biomarker for oral squamous cell carcinoma screening. Biomed Pharmacother. 2020;121:109553. [view at publisher] [DOI] [PMID] [Google Scholar]
39. Lin S-C, Liu C-J, Lin J-A, Chiang W-F, Hung P-S, Chang K-W. miR-24 up-regulation in oral carcinoma: positive association from clinical and in vitro analysis. Oral Oncol. 2010;46(3):204-8. [view at publisher] [DOI] [PMID] [Google Scholar]
40. Salazar-Ruales C, Arguello J-V, López-Cortés A, Cabrera-Andrade A, Garcia-Cardenas JM, Guevara-Ramirez P et al. Salivary MicroRNAs for early detection of head and neck squamous cell carcinoma: A case-control study in the high altitude mestizo ecuadorian population. BioMed research international. 2018;2018. [view at publisher] [DOI] [PMID] []
41. Min S-K, Jung SY, Kang HK, Park S-A, Lee JH, Kim M-J, et al. Functional diversity of miR-146a-5p and TRAF6 in normal and oral cancer cells. Int J Oncol. 2017;51(5):1541-52. [view at publisher] [DOI] [PMID] [Google Scholar]
42. Emami N, Mohamadnia A, Mirzaei M, Bayat M, Mohammadi F, Bahrami N. miR-155, miR-191, and miR-494 as diagnostic biomarkers for oral squamous cell carcinoma and the effects of Avastin on these biomarkers. J Korean Association Oral Maxillofacial Surg. 2020;46(5):341-7. [view at publisher] [DOI] [PMID] []
43. Ries J, Baran C, Wehrhan F, Weber M, Neukam FW, Krautheim-Zenk A, et al. Prognostic significance of altered miRNA expression in whole blood of OSCC patients. Oncol Rep. 2017;37(6):3467-74. [view at publisher] [DOI] [PMID] [Google Scholar]
44. Ries J, Vairaktaris E, Agaimy A, Kintopp R, Baran C, Neukam FW, et al. miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood. Oncol Rep. 2014;31(3):1429-36. [view at publisher] [DOI] [PMID] [Google Scholar]
45. Ries J, Vairaktaris E, Kintopp R, Baran C, Neukam FW, Nkenke E. Alterations in miRNA expression patterns in whole blood of OSCC patients. In vivo. 2014;28(5):851-61. [view at publisher] [PubMed] [Google Scholar]
46. Narimani A, Hosseini F, Bahrami N, Mohamadnia A. The Expression of MicroRNA-155 (miR-155) and Carcinoembryonic Antigen Messenger RNA (CEA mRNA) in Peripheral Blood of Patients with Oral Squamous Cell Carcinomas (OSCC). J Isfahan Med Sch. 2019; 36(510):1597-601. [view at publisher] [DOI] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
